RNA splicing alterations in lung cancer pathogenesis and therapy

Related Experiment Video

Updated: Jul 4, 2025

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.7K

Yueren Yan1, Yunpeng Ren2, Yufang Bao2

  • 1Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.

Cancer Pathogenesis and Therapy
|February 8, 2024
PubMed

Insights

Altered RNA splicing is a key feature in lung cancer development and treatment. Targeting these splicing changes offers new therapeutic strategies for this deadly disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer is a leading cause of cancer death, characterized by significant heterogeneity.
  • Multi-omics studies have revealed extensive transcriptional and post-transcriptional alterations in lung cancer.
  • Altered RNA splicing is increasingly recognized as a critical factor in lung cancer pathogenesis and a potential therapeutic target.

Purpose of the Study:

  • To review splicing dysregulation in lung cancer.
  • To summarize recent advances in understanding key splicing events and factors in lung cancer.
  • To discuss therapeutic strategies targeting RNA splicing in lung cancer.

Main Methods:

  • Literature review of multi-omics studies and research on RNA splicing in lung cancer.
  • Analysis of key splicing events and splicing factors implicated in lung cancer.
  • Overview of current and emerging therapeutic strategies targeting splicing.

Main Results:

  • Splicing alterations are prevalent and contribute significantly to lung cancer.
  • Specific splicing events and factors are identified as drivers of lung cancer.
  • Targeting splicing represents a promising therapeutic avenue.

Conclusions:

  • Splicing dysregulation is a crucial aspect of lung cancer biology.
  • Modulating RNA splicing, potentially in combination with existing therapies, holds promise for improved lung cancer treatment.
  • This review offers insights into splicing dysregulation for mechanistic and therapeutic advancements.
Keywords:
Lung cancerRNA splicingSplicing alterationsSplicing factors

More Related Videos

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

9.0K
Using the E1A Minigene Tool to Study mRNA Splicing Changes10:25

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Published on: April 22, 2021

4.9K

Related Concept Videos

RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
56.4K
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
21.2K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Nucleotide Excision Repair01:38

Nucleotide Excision Repair

DNA Distortion and Damage
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
3.5K
Chromatin Structure Regulates pre-mRNA Processing02:41

Chromatin Structure Regulates pre-mRNA Processing

In eukaryotic cells, nascent mRNA transcripts need to undergo many post-transcriptional modifications to reach the cell cytoplasm and translate into functional proteins. For a long time, transcription and pre-mRNA processing were considered two independent events that occur sequentially in the cell. However, it has now been well established that transcription and pre-mRNA processing are two simultaneous processes that are precisely regulated inside the cell.
The chromatin structure, especially...
7.0K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K